RefleXion Medical Inc. specializes in developing a biologically-guided radiotherapy system aimed at transforming cancer treatment. The company’s innovative technology allows tumors to continuously signal their location during therapy, facilitating the simultaneous treatment of multiple tumors, particularly in cases of metastasis. The RefleXion X1 machine is currently cleared for various forms of radiotherapy, including stereotactic body radiotherapy (SBRT) and intensity-modulated radiotherapy (IMRT). At the core of RefleXion's approach is the integration of positron-emission tomography (PET) imaging, which enables real-time tumor tracking and dose adaptation based on the biological characteristics of the tumors. This advancement in radiotherapy promises to enhance precision in cancer treatment, offering a potential paradigm shift in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic collaborations, including partnerships with Telix Pharmaceuticals and HealthMyne.
Creating novel bispecific antibodies that activate the immune system to fight cancer
Iterative Scopes provides doctors with real-time computer-aided detection and diagnostic tools powered by computer vision and machine learning technology that improves patient outcomes by helping gastroenterologists detect and categorize lesions in real-time, including those that often elude the human eye, and bring care worldwide by providing doctors with access to deep neural networks trained by experienced GI specialists.
Iterative Scopes was founded on 2017 and is headquartered in Cambridge, Massachusetts.
Innovation in healthcare is hindered by the time and cost of bringing new products to market. Verana Health is partnering with medical associations to build a regulatory-grade data platform for health care innovation that utilizes specialty clinical data sets. Verana Health’s platform enables physicians and industry to work together towards their shared goal of accelerating the availability of better treatments and cures for patients. Learn more at veranahealth.com.
AviadoBio mission is to transform the lives of people living with neurodegenerative disorders by developing and delivering transformative gene therapies for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The Company’s technology is based on pioneering research from King’s College London and the UK Dementia Research Institute.
Mauna Kea Technologies is a global medical device company headquartered in Paris, France, that specializes in the development and marketing of technologies aimed at improving the diagnosis and treatment of cancers and other diseases. Founded in 2000, the company’s flagship product, Cellvizio, is a confocal laser endomicroscopy platform that enables real-time in vivo microscopic visualization of tissues at the cellular level. This innovative technology provides physicians and researchers with critical imaging capabilities, enhancing diagnostic accuracy and treatment effectiveness. Cellvizio has received regulatory clearance and approval for various applications in the United States and over 40 countries worldwide, underscoring its significance in the medical field.
FlexDex Inc. specializes in the development of minimally invasive surgery (MIS) devices, focusing on enhancing surgical precision and dexterity. The company's innovative platform technology allows surgeons to translate their hand, wrist, and arm movements from outside the patient into corresponding movements of an end-effector within the patient's body. This capability improves the functionality of MIS instruments and endoscopes, making procedures safer and more efficient. FlexDex serves healthcare professionals through a network of distributors both in the United States and internationally. Founded in 2010 and based in Brighton, Michigan, FlexDex continues to advance the field of minimally invasive surgery.
Visus Therapeutics is a clinical-stage company developing innovative medicines to improve the vision for people around the world.
Iterative Scopes provides doctors with real-time computer-aided detection and diagnostic tools powered by computer vision and machine learning technology that improves patient outcomes by helping gastroenterologists detect and categorize lesions in real-time, including those that often elude the human eye, and bring care worldwide by providing doctors with access to deep neural networks trained by experienced GI specialists.
Iterative Scopes was founded on 2017 and is headquartered in Cambridge, Massachusetts.
POINT Biopharma Global Inc. is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. POINT Biopharma Global Inc. is combining a portfolio of best-in-class radiopharmaceutical assets, a seasoned management team, expertise in radioisotopes such as Actinium-225 (Ac-225) and Lutetium-177 (Lu-177), manufacturing technology and novel direct-to-patient targeting to revolutionize theragnostic drug development and radioligand commercialization.
Ribon Therapeutics, Inc. is a biotechnology company based in Lexington, Massachusetts, founded in 2015. The company is focused on developing innovative cancer therapies that target monoPARP proteins, which are essential regulators of cancer cell survival. Ribon's scientific founders have made significant contributions to the understanding of PARPs, or poly(ADP-ribose) polymerases, and their roles in cancer. Leveraging this expertise, Ribon is establishing a proprietary drug discovery platform aimed at exploring the molecular actions and biological functions of monoPARPs. This platform supports the creation of a pipeline of therapeutics that selectively target these proteins to potentially treat cancer and other diseases. Ribon Therapeutics is supported by notable life science investors, enhancing its capability to advance its research and development efforts.
Thirty Madison, Inc. is a digital health company based in Astoria, New York, focused on providing specialized care for chronic conditions through its web-based platforms. Founded in 2016, the company operates several condition-specific brands: Keeps, which offers a subscription service for men's hair loss prevention medications; Cove, which provides online consultations and prescriptions for migraine treatment; and Evens, designed to manage acid reflux. By offering these tailored services, Thirty Madison aims to increase access to affordable healthcare solutions, addressing the unique needs of patients suffering from these conditions.
Pulmocide Ltd, a company focused on the discovery and development of a new generation of inhaled medicines for the treatment of serious viral and fungal infections of the respiratory tract.
Private Equity Round in 2021
Cue Health Inc. is a San Diego-based healthcare technology company that specializes in the development and manufacturing of medical diagnostic products designed for easy use in various settings, including clinics, schools, and senior living facilities. The company offers the Cue Health Monitoring System, a connected diagnostic platform that allows healthcare professionals to access essential health information through self-serve tests, providing results directly to mobile devices. Additionally, Cue Health provides test cartridges and a consumer software application that features a personalized health dashboard, storing test results and enabling connections to on-demand telemedicine and prescription services. The platform also supports healthcare professionals in managing patient test histories and facilitating follow-up consultations, including telemedicine options. Founded in 2010, Cue Health aims to empower individuals with the ability to track key health indicators, such as inflammation, vitamin D levels, fertility, influenza, and testosterone, at the molecular level from the comfort of their homes.
Sunday2Sunday is an emerging textured hair care company that focuses on bringing ingredients and products to its customer's doorstep. It specializes in the fields of beauty, healthcare, and consumer goods. It was founded in 2019 and headquartered in Brooklyn, New York.
Visus Therapeutics is a clinical-stage company developing innovative medicines to improve the vision for people around the world.
TechsoMed is an Israeli based medical device company, developing ultrasound based real-time monitoring systems for thermal ablation procedures. The applications of thermal ablation are numerous: tumor destruction, heart arrhythmia, blood pressure treatments and more. The procedure has market size in the billions, but lacks real-time monitoring capabilities, causing high failure rates.
Their technology offers added value to patients, physicians and insurance companies by solving the high failure rate of these minimally invasive and cost effective procedures.
Paige builds software to advance the diagnosis, treatment, and biomarker discovery for cancer. The Memorial Sloan Kettering spin-out aims to help pathologists and clinicians make faster, more informed diagnostic and treatment decisions and to bring new digital biomarkers to their practice. Paige’s proprietary Machine Learning solutions provide insights from decades of data from the world’s experts in cancer care and were recently published in Nature Medicine. The company’s first product for prostate cancer detection received Breakthrough Designation from the FDA as a novel therapy that stands to improve diagnostic accuracy while reducing costs to health systems.
ONL Therapeutics is a biopharmaceutical company dedicated to protecting vision through the protection of photoreceptors. The current market for retinal drugs is greater than $7 billion and rapidly growing. Existing therapies have significant limitations and none address the initial neural component of vision loss - the death of the photoreceptor cell.
Datavant, Inc. is a healthcare data platform that aggregates and analyzes biomedical data using machine learning and artificial intelligence. Founded in 2017 and based in San Francisco, the company focuses on enhancing the clinical trial process by organizing and structuring healthcare data to provide actionable insights. Datavant's services cater to the clinical development and commercial pharmaceutical sectors, as well as researchers, by facilitating the protection, matching, and sharing of health data. The platform is designed to help pharmaceutical companies manage privacy, security, compliance, and trust, thereby enabling safe data sharing and improving the design and interpretation of clinical trials.
Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Regulating synaptic transmission represents a promising approach to treating Alzheimer’s Disease and other disorders with cognitive impairment. Syndesi has an exclusive license to its platform technology from UCB, the leading company in SV2A research.
V-Wave Ltd. is a medical technology company based in Caesarea, Israel, with additional offices in the United States. Founded in 2009, it specializes in the development of percutaneous implantable therapeutic devices aimed at treating chronic heart failure (HF) patients, which is a major cause of morbidity and mortality worldwide. The company has created the V-Wave Shunt, a biocompatible inter-atrial unidirectional implant designed for patients with both preserved and reduced ejection fractions, addressing the needs of those who experience disabling symptoms despite optimal medical therapy. V-Wave's innovative approach focuses on relieving symptoms, reducing hospitalizations, enhancing exercise capacity, and improving overall quality of life for HF patients. The organization is backed by a team of experienced engineers and medical scientists who have a proven track record in developing and bringing various implantable cardiovascular devices to market.
Sunday2Sunday is an emerging textured hair care company that focuses on bringing ingredients and products to its customer's doorstep. It specializes in the fields of beauty, healthcare, and consumer goods. It was founded in 2019 and headquartered in Brooklyn, New York.
Aetion, Inc. develops a science and analytics platform to assess real-world evidence (RWE) from a range of sources. The company offers Aetion Evidence Platform, a platform that generates RWE needed by healthcare decision makers to engage in value-based care. Its solution allows payers, providers, medical device makers, biopharma customers, and academic institutions to analyze data from various clinical and financial interactions in healthcare, including claims, electronic health records, registries, and clinical trials. The company’s platform is also used in database analytics and comparative effectiveness courses taken by epidemiologists, outcomes researchers, health economists, and biostatisticians. It serves customers worldwide. Aetion, Inc. has a strategic collaboration with McKesson. The company was founded in 2012 and is based in New York, New York.
G.I. Windows is a clinical-stage company developing the first fundamental breakthrough in surgical anastomotic technology. This technology will allow less invasive surgery and offer the capability of developing more procedures new to the world. The company is creating a new category in healthcare designed to create less invasive surgery and reduce healthcare costs.
G.I. Windows is committed to innovation that helps improve the way diagnostic and interventional procedures impact the essential balance between both patients and the healthcare system.
It was founded in 2012 and is headquartered in West Bridgewater, Massachusetts, United States.
ImmPACT Bio USA Inc. is a cell therapy company aiming to develop potent and selective engineered T-cells for the treatment of solid tumors. The Company's technology enables targeting loss-of-gene features of solid tumor cells, sparing normal, healthy tissues.
Thirty Madison, Inc. is a digital health company based in Astoria, New York, focused on providing specialized care for chronic conditions through its web-based platforms. Founded in 2016, the company operates several condition-specific brands: Keeps, which offers a subscription service for men's hair loss prevention medications; Cove, which provides online consultations and prescriptions for migraine treatment; and Evens, designed to manage acid reflux. By offering these tailored services, Thirty Madison aims to increase access to affordable healthcare solutions, addressing the unique needs of patients suffering from these conditions.
Vor Biopharma, Inc. develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It offers VOR33, an eHSC product candidate that is in preclinical development to treat acute myeloid leukemia (AML). The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML cancer cells. Vor Biopharma, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.
Cue Health Inc. is a San Diego-based healthcare technology company that specializes in the development and manufacturing of medical diagnostic products designed for easy use in various settings, including clinics, schools, and senior living facilities. The company offers the Cue Health Monitoring System, a connected diagnostic platform that allows healthcare professionals to access essential health information through self-serve tests, providing results directly to mobile devices. Additionally, Cue Health provides test cartridges and a consumer software application that features a personalized health dashboard, storing test results and enabling connections to on-demand telemedicine and prescription services. The platform also supports healthcare professionals in managing patient test histories and facilitating follow-up consultations, including telemedicine options. Founded in 2010, Cue Health aims to empower individuals with the ability to track key health indicators, such as inflammation, vitamin D levels, fertility, influenza, and testosterone, at the molecular level from the comfort of their homes.
Cue Health Inc. is a San Diego-based healthcare technology company that specializes in the development and manufacturing of medical diagnostic products designed for easy use in various settings, including clinics, schools, and senior living facilities. The company offers the Cue Health Monitoring System, a connected diagnostic platform that allows healthcare professionals to access essential health information through self-serve tests, providing results directly to mobile devices. Additionally, Cue Health provides test cartridges and a consumer software application that features a personalized health dashboard, storing test results and enabling connections to on-demand telemedicine and prescription services. The platform also supports healthcare professionals in managing patient test histories and facilitating follow-up consultations, including telemedicine options. Founded in 2010, Cue Health aims to empower individuals with the ability to track key health indicators, such as inflammation, vitamin D levels, fertility, influenza, and testosterone, at the molecular level from the comfort of their homes.
HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels.
GATT Technologies BV develops synthetic surgical hemostat and sealant products that control severe bleeding. The company provides products, such as GATT-Patch, a hemostatic sealing patch for general surgery; GATT-Tape, a tape for preventing intestinal anastomotic leakage; GATT-Spray, an adhesive elastic sealant for general surgery; and GATT-Powder, a hemostatic sealing powder. GATT Technologies BV was founded in 2011 and is based in Nijmegen, the Netherlands.
RefleXion Medical Inc. specializes in developing a biologically-guided radiotherapy system aimed at transforming cancer treatment. The company’s innovative technology allows tumors to continuously signal their location during therapy, facilitating the simultaneous treatment of multiple tumors, particularly in cases of metastasis. The RefleXion X1 machine is currently cleared for various forms of radiotherapy, including stereotactic body radiotherapy (SBRT) and intensity-modulated radiotherapy (IMRT). At the core of RefleXion's approach is the integration of positron-emission tomography (PET) imaging, which enables real-time tumor tracking and dose adaptation based on the biological characteristics of the tumors. This advancement in radiotherapy promises to enhance precision in cancer treatment, offering a potential paradigm shift in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic collaborations, including partnerships with Telix Pharmaceuticals and HealthMyne.
OrthoSpin is developing innovative robotic external fixation system that will improve patient treatment and allow a real-time review to reduce complications and improve clinical outcomes. Dynamic external fixators are mainly used for trauma, bone lengthening and congenital deformities correction. Those systems are cumbersome, painful and require high maintenance.
With OrthoSpin’s smart system, physicians are assured that the prescribed course of treatment is being followed. The Company’s proprietary software program allows physicians to chart patient progress and, if required, to easily change the treatment schedule.
AviadoBio mission is to transform the lives of people living with neurodegenerative disorders by developing and delivering transformative gene therapies for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The Company’s technology is based on pioneering research from King’s College London and the UK Dementia Research Institute.
Mauna Kea Technologies is a global medical device company headquartered in Paris, France, that specializes in the development and marketing of technologies aimed at improving the diagnosis and treatment of cancers and other diseases. Founded in 2000, the company’s flagship product, Cellvizio, is a confocal laser endomicroscopy platform that enables real-time in vivo microscopic visualization of tissues at the cellular level. This innovative technology provides physicians and researchers with critical imaging capabilities, enhancing diagnostic accuracy and treatment effectiveness. Cellvizio has received regulatory clearance and approval for various applications in the United States and over 40 countries worldwide, underscoring its significance in the medical field.
ProteKt Therapeutics is a drug development company aiming to develop potent and selective oral inhibitors of the kinase PKR for the treatment of neurodegenerative and neuroinflammatory diseases. The company has raised a $4M pre-A round and graduated from the FutuRx accelerator in 2019.
X-Vax Technology is a biotechnology company focused on the preclinical and clinical development of vaccines against pathogens that cause mucosal infections such as herpes, influenza, tuberculosis and HIV, affecting hundreds of millions of people around the globe. They believe that inducing antibodies that mediate the killing of infected cells will provoke an entirely new and effective immune response – so that they can finally beat these pathogens. The company was founded in 2015 and based in Jupiter, Florida.
Cara by HiDoc Technologies is a pharmaceutical company based in Berlin, Germany, focused on improving the lives of patients with chronic digestive diseases. Established in 2015, Cara develops companion digital therapeutics that complement existing treatments for gastrointestinal disorders. One of their key offerings is a personal food and symptom diary, which helps patients track their dietary habits and symptoms, thereby enhancing the overall management of their conditions. By integrating innovative digital solutions with traditional therapies, Cara aims to empower patients and improve their quality of life.
BlackThorn Therapeutics operator of a clinical-stage biopharmaceutical company intended to develop precision medicine for disorders of the central nervous system (CNS) based on advances in computational and clinical neuroscience. The company leverages a deep understanding of brain and behavior relationships that seeks to overcome historic challenges in drug discovery and development by targeting dysfunctional brain circuits. Its proprietary computational platform, the company seeks to identify novel targets, small molecule drug candidates and biologically-based patient subgroups most likely to respond to treatment.
TechsoMed is an Israeli based medical device company, developing ultrasound based real-time monitoring systems for thermal ablation procedures. The applications of thermal ablation are numerous: tumor destruction, heart arrhythmia, blood pressure treatments and more. The procedure has market size in the billions, but lacks real-time monitoring capabilities, causing high failure rates.
Their technology offers added value to patients, physicians and insurance companies by solving the high failure rate of these minimally invasive and cost effective procedures.
Cala Health, Inc. is a bioelectronic medicine company focused on developing innovative therapies for chronic diseases. Based in Burlingame, California, the company specializes in wearable neuromodulation devices that utilize advancements in neuroscience and technology to provide individualized peripheral nerve stimulation. Its flagship product, Cala Trio, is a non-invasive therapy designed to offer relief from hand tremors in adults with essential tremor, a condition affecting millions. In addition to its current offerings, Cala Health is actively developing new therapeutic solutions in the fields of neurology, cardiology, and psychiatry, aiming to enhance the standard of care for patients with chronic conditions. Founded in 2013, the company has garnered support from prominent investors in both the healthcare and technology sectors.
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada.
Vor Biopharma, Inc. develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It offers VOR33, an eHSC product candidate that is in preclinical development to treat acute myeloid leukemia (AML). The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML cancer cells. Vor Biopharma, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.
Memebox Corporation is a consumer company that provides customers with the Asian beauty products, culture, and trends. A global company focused on forecasting trends and creating private, in-house labels inspired by K-beauty (and made for the product obsessed).
Ribon Therapeutics, Inc. is a biotechnology company based in Lexington, Massachusetts, founded in 2015. The company is focused on developing innovative cancer therapies that target monoPARP proteins, which are essential regulators of cancer cell survival. Ribon's scientific founders have made significant contributions to the understanding of PARPs, or poly(ADP-ribose) polymerases, and their roles in cancer. Leveraging this expertise, Ribon is establishing a proprietary drug discovery platform aimed at exploring the molecular actions and biological functions of monoPARPs. This platform supports the creation of a pipeline of therapeutics that selectively target these proteins to potentially treat cancer and other diseases. Ribon Therapeutics is supported by notable life science investors, enhancing its capability to advance its research and development efforts.
MultiScale Health Networks LLC develops and markets cloud based data platform and application that provides real time data access to healthcare industry. The application extracts, aggregates, and optimizes operational intelligence from emergency department and share patient data across care operations. The platform provides data access to multi-disciplinary team, and allows communication and collaboration across different teams. MultiScale Health Networks LLC was founded in 2012 and is based in Seattle, Washington.
Carrot Inc. is a company based in Redwood City, California, that specializes in smoking cessation through its application, Pivot. Founded in 2015, Carrot offers a unique six-stage program that engages smokers early in their journey without imposing pressure to quit. The program begins by fostering awareness of smoking habits and enhancing confidence in the smoker's ability to change. For those who choose to pursue cessation, Pivot assists users in creating and implementing a personalized quit plan, supported by one-on-one coaching until they achieve stability in their quit journey. This approach emphasizes self-motivation and personal commitment, distinguishing Carrot's service in the field of smoking cessation.
Curasen Therapeutics Inc. operates as a biotechnology company which develops therapies to treat neurodegenerative diseases. It also develops small molecule drugs that targets a novel mechanism in the brain to restore function, improve symptoms, and modify diseases, such as less common (orphan) neurodegenerative disorders, and Parkinson's disease and Alzheimer's disease. The company was incorporated in 2016 and is based in Los Altos, California.
PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company based in Malvern, Pennsylvania, focused on developing innovative therapies for cardiopulmonary diseases. Its lead product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor and is currently undergoing Phase III clinical trials for patients experiencing uncontrolled bleeding or requiring urgent surgery. The company is also advancing PB1046, a fusion protein aimed at treating pulmonary arterial hypertension, which is in Phase IIb clinical trials. Additionally, PhaseBio is developing PB6440, an oral agent intended for the treatment of resistant hypertension. Founded in 2002, the company leverages proprietary recombinant biopolymers to enhance the stability and efficacy of its drug candidates.
OrthoSpin is developing innovative robotic external fixation system that will improve patient treatment and allow a real-time review to reduce complications and improve clinical outcomes. Dynamic external fixators are mainly used for trauma, bone lengthening and congenital deformities correction. Those systems are cumbersome, painful and require high maintenance.
With OrthoSpin’s smart system, physicians are assured that the prescribed course of treatment is being followed. The Company’s proprietary software program allows physicians to chart patient progress and, if required, to easily change the treatment schedule.
S-Biomedic is a Belgian biotech company specializing in live probiotic cosmetics designed to improve skin health. The company focuses on the skin microbiome, a complex ecosystem of beneficial and harmful bacteria that plays a crucial role in skin conditions such as acne, eczema, rosacea, and aging. S-Biomedic employs advanced modulation-based technology to selectively harness beneficial bacteria, creating products that promote the rebalancing of the skin microbiome. By utilizing the latest advancements in microbiology and dermatology, their offerings aim to restore healthy skin and address various dermatological concerns. Through this innovative approach, S-Biomedic provides therapeutic solutions in both the dermatology and cosmetic sectors, enhancing the overall health and beauty of the skin.
Zebra Medical Vision Ltd. is an Israeli company founded in 2014 that specializes in developing an imaging analytics platform aimed at enhancing healthcare delivery. The platform provides a comprehensive suite of imaging research solutions for clinicians, advanced machine learning and computer vision diagnostic algorithms for developers, and risk management tools for healthcare providers. By offering access to a vast repository of anonymized clinical records, Zebra Medical Vision supports researchers in accelerating the development of decision support tools and improving diagnostic accuracy. The company collaborates with various partners, including USARAD Holdings and TELUS Ventures, to leverage its network of over 1,100 hospitals and healthcare providers. This collaboration fosters innovation and enhances patient care through the application of advanced analytics and automated clinical insights, positioning Zebra Medical Vision as a leader in the integration of AI and machine learning in medical imaging.
NeuroVision Imaging LLC is a neuroscience company based in Sacramento, California, focused on developing digital imaging and diagnostic solutions for Alzheimer's disease and eye care markets. Established in 2010, the company specializes in creating diagnostic tests and biomarkers tailored for the early detection and monitoring of amyloid pathology associated with Alzheimer's disease. NeuroVision has developed an innovative retinal imaging technology that is currently employed in various clinical trials worldwide. Additionally, the company offers data aggregation services, along with analysis, biostatistics, and machine learning applications to leverage large datasets of images and biomarker information. This multifaceted approach aims to enhance the understanding and predictive capabilities regarding neurodegenerative diseases, serving both domestic and international clients.
Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Regulating synaptic transmission represents a promising approach to treating Alzheimer’s Disease and other disorders with cognitive impairment. Syndesi has an exclusive license to its platform technology from UCB, the leading company in SV2A research.
On Target Laboratories, LLC engages in discovering, developing, and commercializing small molecules that target specific pathological cells, when conjugated with fluorescent dyes. It offers folate and other targeting agents that target, lung, uterine, kidney, breast, colon, pancreatic, and prostate cancer cells. The company was incorporated in 2010 and is based in Northbrook, Illinois.
Pulmocide Ltd, a company focused on the discovery and development of a new generation of inhaled medicines for the treatment of serious viral and fungal infections of the respiratory tract.
Cala Health, Inc. is a bioelectronic medicine company focused on developing innovative therapies for chronic diseases. Based in Burlingame, California, the company specializes in wearable neuromodulation devices that utilize advancements in neuroscience and technology to provide individualized peripheral nerve stimulation. Its flagship product, Cala Trio, is a non-invasive therapy designed to offer relief from hand tremors in adults with essential tremor, a condition affecting millions. In addition to its current offerings, Cala Health is actively developing new therapeutic solutions in the fields of neurology, cardiology, and psychiatry, aiming to enhance the standard of care for patients with chronic conditions. Founded in 2013, the company has garnered support from prominent investors in both the healthcare and technology sectors.